In a Phase 1/2 study, FX-322 demonstrated a statistically significant and clinically meaningful improvement in key measures of hearing loss, including clarity of sound and word recognition, with no serious adverse events observed.
GN Hearing CEO Anders Hedegaard has resigned after accepting a position as CEO in another company outside of the hearing industry. Marcus Desimoni will act as interim CEO of GN Hearing, in parallel with his role as CFO of GN Store Nord and GN Hearing, until a new CEO for GN Hearing is appointed.
A new approach, published in “Cell Reports,” to regenerate inner ear sensory hair cells is said to lay the groundwork for treating chronic noise-induced hearing loss by the company, Frequency Therapeutics, and its co-founders who are drawing on research from Brigham and Women's Hospital (BWH), Harvard Medical School, Mass Eye and Ear Infirmary, and MIT. The program is expected to progress to into human clinical trials within the next 18 months.
Audiologists from around the world will meet in Louisville to discuss the benefits and pitfalls of using the Internet for research and hearing health care (telehealth) for individuals with hearing impairment.